下肢缺血预处理对未成熟心肌的保护作用及其机制

目的　探讨下肢缺血预处理对未成熟心肌保护作用的机制。方法　采用双下肢缺血预处理 (DLIP)大白兔Langendorff离体心脏灌注模型。分为 4组 ,每组大白兔 6只 :E1组 ,动物麻醉后反复 3次阻断双下肢血流 5min ,松开 5min ,建立模型 ,灌注 15min转为工作心 15min ,全心停灌 45min ,恢复灌注 15min改为工作心 3 0min ;E2组 ,双下肢缺血预处理前静脉注射超氧化物歧化酶至双下肢缺血预处理完毕 ,重复E1组方法 ;E3组 ,静脉注射蛋白激酶C(PKC)阻滞剂多粘菌素B(PMB) ,时间 10min ,重复E1组方法 ;E4组 ,静脉注射ATP敏感性钾通道 (mitoKATP)阻滞剂(5 HD) ,时间 10min ,重复E1组方法。以左室功能恢复、心肌含水量、血清肌酸激酶 (CK )和乳酸脱氢酶 (LDH)漏出率、心肌组织ATP和丙二醛 (MDA)含量、超氧化物歧化酶 (SOD)活性、心肌细胞内Ca2 含量、心肌线粒体钙依赖性ATP酶 (Ca2 ATPase)活性及其Ca2 含量、心肌线粒体合成ATP能力 [ATP] m、超氧阴离子自由基 (O2 -)作为观察指标。结果　E1组左心室功能恢复优于其他各组 (P <0 .0 5 ) ,心肌ATP含量、SOD活性、Ca2 ATPase活性、[ATP] m 均优于其他各组 (P <0 .0 1) ,心肌含水量低于其他各组 (P <0 .0 5 ) ,MDA含量、CK、LDH漏出率、心肌细胞内Ca2 含量、心肌     

阿片受体对体外循环缺血再灌注损伤心肌的保护作用

目的 通过建立猪体外循环(CPB)心肌缺血再灌注(MI/R)模型对δ阿片受体激动剂脑腓肽(DADLE)介导的CPB MI/R损伤早期时相和后时相的心肌保护作用进行探讨,以期为临床心肌保护提供理论和实验依据.方法 将24只成年家猪随机分为对照组、早期时相和后时相组,每组8只常规建立CPB模型,主动脉阻断同时灌注改良St.Thomas停搏液.每组于CPB前、主动脉开放时、CPB结束时、停机后1、2 h检测冠状静脉窦血肌钙蛋白(TnT)含量,相应时间点监测左室舒张末期压(LVEDP)和左室内压最大变化速率(±ap/dt<,max>),于停机后2h取左心室心肌,进行心肌组织Gia蛋白的表达、PKC的表达和ATP含量的测定.并应用透射电镜观察心肌再灌注损伤超微结构的变化.结果 (1)和早期时相和后时相组相比,对照组心功能指标明显下降.(2)对照组的TnT较早期时相和后时相组明显升高,ATP含量明显降低.(3)和对照组相比,早期时相和后时相组Gin蛋白和PKC的表达更为明显.(4)透射电镜下早期时相和后时相组的心肌超微结构损伤均较对照组明显轻微.结论 (1)和CPB前1 h应用一次DADLE而产生的早期时相心肌保护作用相比,CPB前48 h和24 h两次应用DADLE引发的后时相心肌保护作用更为显著.(2)Gi蛋白-PKC途径可能是δ阿片受体介导的猪CPB NI/R损伤心肌保护中一条重要的信号传导途径.     

Cardioprotection by nisoldipine: role of timing of administration

Nisoldipine was administered at 10^–9M, a dose lackingnegative inotropism, to isolated and perfused rabbit heartssubmitted to 60 min ischaemia (1 ml.min^–1) followed by30 min reperfusion. The drug was delivered either 30 min beforeischaemia, at the onset and after 30 min of ischaemia and duringreperfusion only. Cardiac protection was evaluated in termsof recovery of left ventricular pressure during reperfusion,release of creatine phosphokinase (CPK), mitochondrial function,tissue content of adenosine triphosphate (ATP) and creatinephosphate (CP), calcium homeostasis and the occurrence of oxidativestress, established measuring content and release of reducedand oxidized glutathione. The cytoprotective action of nisoldipine occurs in the absenceof negative inotropism and is closely related to the time ofadministration. Optimal myocardial preservation is achievedwhen nisoldipine is given before or at the onset of ischaemia.Prophylactic administration of nisoldipine improved the recoveryof the developed pressure from 159±10 (SE) mmHg to 478±19mmHg, P<0.01 and reduced the release of CPK from 830±29to 229±27 mU. min^–1 g^–1 wet wt, P<0.01.The accumulation of tissue and mitochondrial calcium was reducedfrom58±11 and49±9 to 14±6 and 10±4 mmol.kg^–1 dry wt respectively, P<0.01. This resulted ina signficant (P<0.01) preservation of all indices of mitochondrialfunction, allowing a higher recovery of ATP and CP after reperfusion(from 4.1±0.7 and 10.0±0.6 to 16.1±1.0and 29.9±0.2 µmol.g^–1 dry wt respectively,P<0.001). Reperfusion-induced myocardial accumulation and release of oxidizedglutathione were reduced from 0.493±0.07 nmol.mg^–1protein and 0.768±0.063 nmol.min^–1g^–1 wetwt to 0.225±0.07 and 0.157±0.038 respectively,P<0.01. Similar data were obtained when nisoldipine was givenat the time of ischaemia, while administration 30 min afterthe onset of ischaemia showed only a trend towards protection.Nisoldipine lost its protective effect when given on reperfusion. A multifactorial analysis of the data suggest that the cardioprotectiveeffect of nisoldipine is related to the maintenance of membraneintegrity, possibly since nisoldipine is highly lipophilic.     

温血高钾间断灌注心肌保护的临床应用

目的　探讨浅低温体外循环 (CPB)温血间断灌注心肌保护的临床效果。方法　全组随机分为对照组 (A组 )6 8例 ,采用浅低温CPB温血高钾持续灌注心肌保护。实验组 (B组 ) 91例 ,采用浅低温CPB温血高钾间断灌注心肌保护。观察两组术中心肌保护效果的差别。结果　CPB时间、主动脉阻断时间B组明显小于A组 (P <0 .0 5 ) ;库血用量和 2 4h胸腔引流量B组明显少于A组 (P <0 .0 5 ) ;主动脉开放前血钾浓度B组明显低于A组 (P <0 .0 5 ) ;主动脉开放后心脏自动复跳率B组明显高于A组 (P <0 .0 5 ) ;术后心功能临床观察两组无显著差异。结论　浅低温CPB温血高钾间断灌注保护心肌效果良好。     

不同部位缺血预处理对未成熟心肌保护作用的研究

目的探讨不同部位缺血预处理对未成熟心肌保护作用。方法采用经典心脏缺血预处理、肾缺血预处理及双下肢缺血预处理动物Langendorff灌注模型比较三种方法对缺血 /再灌(I/R)未成熟心肌损伤的效应。分为5组 :正常对照组(NC,n=6) ,离体心脏仅灌注KH液70min;缺血 /再灌 (I/R ,n=6) ,离体心脏灌注15min转为工作心15min后停灌45min,恢复灌注15min改为工作心30min;心脏缺血预处理组 (IPC,n=6),离体心脏灌注15min转为工作心15min后反复2次缺血5min/再灌5min,然后重复I/R组方法 ;肾缺血预处理组(K -IPC ,n=6) ,反复3次阻断左肾动脉5min,放开5min,然后重复I/R组方法。双下肢缺血预处理组 (DL-IPC ,n=6) ,反复3次捆扎双下肢5min,松开5min,然后重复I/R组方法。以左心室功能恢复、心肌含水量、血清肌酸激酶 (CK)和乳酸脱氢酶 (LDH)漏出率 ,心肌组织ATP和丙二醛 (MDA)含量、超氧化物歧化酶(SOD)活性及电镜作为观察指标。结果IPC、DL-IPC及K-IPC组在左心室功能恢复优于I/R组 (P<0.05) ,在ATP含量、SOD活性及心肌超微结构方面均优于I/R组(P<0.01) ,心肌含水量低于I/R组 (P<0.05) ,在MDA含量、CK、LDH漏出率方面均低于I/R组 (P<0.01)。结论不同部位的非心脏缺血预处理 ,与心脏缺血预处理可诱发同等的心肌保护作用     

热休克蛋白70对离体心脏心肌间质的保护作用

目的探讨热休克蛋白70（HSP70）对大鼠离体心脏心肌间质的影响。方法Wistar大鼠16只，分为2组：对照组（C，n=8），腹腔注射生理盐水0．4ml，24h后取离体心脏灌注HTK心脏保护液，4℃保存3h后建立Langendorff灌注模型，灌注KH液2h；实验组（E，n=8），腹腔注射重酒石酸去甲肾上腺素，24h后取离体心脏，方法同对照组。以心肌细胞中HSP70含量、血流动力学指标、心肌组织羟脯氨酸（HP）、内皮索（ET）含量和心肌超微结构等作为观察指标。结果HSP70含量E组与C组比较明显增高；E组心功能恢复方面优于C组（P〈0．05），HP含量优于C组（P〈0．01），ET含量低于C组（P〈0．01），心肌超微结构损伤较C组明显减轻。结论HSP 70对供心心肌间质具有保护作用。     

单纯缺血预处理对未成熟兔心脏的作用研究

目的 探讨缺血预处理（Ｉｓｃｈｅｍｉｃ Ｐｒｏｃｏｎｄｉｔｉｏｎｉｎｇ ＩＰＣ）对未成熟心脏全心缺血再灌注损伤的影响。方法 对经历５Ｍｉｎ缺血、１０Ｍｉｎ再灌注的幼兔（１４～２１天）心脏进行离体灌注,观察其在生理温度（３９℃）下接受３０Ｍｉｎ缺血、４０Ｍｉｎ再灌注的心肌酶释放、心肌能量及病理变化。结果 ＩＰＣ组全心缺血后心脏停跳持续时间显明延长（Ｐ〈０．０１）,心肌ＡＴＰ含量明显减少（Ｐ〈０．００     

Cardioprotection Acquired Through Exercise: The Role of Ischemic Preconditioning

A great bulk of evidence supports the concept that regular exercise training can reduce the incidence of coronary events and increase survival chances after myocardial infarction. These exercise-induced beneficial effects on the myocardium are reached by means of the reduction of several risk factors relating to cardiovascular disease, such as high cholesterol, hypertension, obesity etc. Furthermore, it has been demonstrated that exercise can reproduce the “ischemic preconditioning” (IP), which refers to the capacity of short periods of ischemia to render the myocardium more resistant to subsequent ischemic insult and to limit infarct size during prolonged ischemia. However, IP is a complex phenomenon which, along with infarct size reduction, can also provide protection against arrhythmia and myocardial stunning due to ischemia-reperfusion. Several clues demonstrate that preconditioning may be directly induced by exercise, thus inducing a protective phenotype at the heart level without the necessity of causing ischemia. Exercise appears to act as a physiological stress that induces beneficial myocardial adaptive responses at cellular level. The purpose of the present paper is to review the latest data on the role played by exercise in triggering myocardial preconditioning.     

Therapeutic potential of sulindac against ischemia-reperfusion-induced myocardial infarction in diabetic and nondiabetic rats

BACKGROUND

Diabetes mellitus is an independent risk factor for cardiovascular disease and is also associated with increased susceptibility to cardiovascular complications. It has been suggested that alterations in glucose metabolism and glucose flux via the aldose reductase pathway make the diabetic heart more sensitive to ischemic-reperfusion injury. Previous studies have found sulindac to have inhibitory and anti-inflammatory effects on aldose reductase. The use of aldose reductase inhibitors for the protection of ischemic myocardium is still in an exploratory state.

OBJECTIVES

To evaluate the therapeutic potential of sulindac in an in vivo rat model of acute ischemia (30 min) and reperfusion (4 h) in diabetic and nondiabetic rats.

METHODS

Diabetes was induced in rats by administering streptozotocin (45 mg/kg, intravenously). Myocardial infarction was induced by occlusion of the left anterior descending coronary artery for 30 min followed by 4 h of reperfusion. Infarct size was measured using the staining agent 2,3,5-triphenyltetrazolium chloride. A lead II electrocardiogram was monitored at various intervals throughout the experiment. Sorbitol dehydrogenase levels in heart tissue, as well as lipid peroxide levels in serum and heart tissue, were estimated spectrophotometrically.

RESULTS

Infarct size was increased in diabetic rats in comparison with normal rats. Pretreatment with sulindac significantly reduced infarct size, lipid peroxidation and sorbitol dehydrogenase levels in both diabetic and nondiabetic rats. The degree of cardioprotection was greater in diabetic rats than in nondiabetic rats.

CONCLUSIONS

The present study indicates that the observed cardioprotection provided by sulindac in terms of reducing infarct size in normal rats may be due to its combined antioxidant and anti-inflammatory activities. The inhibition of aldose reductase may be responsible for the enhanced cardioprotection observed in diabetic rats treated with sulindac.